

**SUBSTANTIAL SHAREHOLDERS**

**SUBSTANTIAL SHAREHOLDERS**

So far as our Directors are aware as of the Latest Practicable Date, immediately following the completion of the [REDACTED] (assuming no changes to our issued and outstanding share capital between the Latest Practicable Date and the [REDACTED] and assuming the [REDACTED] is not exercised), the following persons will have interests and/or short positions (as applicable) in the Shares or underlying Shares which would fall to be disclosed to our Company and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, will be, directly or indirectly, interested in 5% or more of the issued voting rights of our Company or any other member of our Group:

<u>Substantial Shareholder</u>	<u>Capacity/Nature of Interest</u>	<u>Total number of Shares/underlying shares</u>	<u>Approximate percentage of interest in our Company upon the completion of the [REDACTED] (assuming the [REDACTED] is not exercised)</u>
WuXi Biologics . . . . .	Beneficial interest	[REDACTED]	[REDACTED]
WuXi AppTec <sup>(1)</sup> . . . . .	Interest in controlled corporation	[REDACTED]	[REDACTED]
WuXi AppTec (Shanghai) . . . . .	Interest in controlled corporation	[REDACTED]	[REDACTED]
STA . . . . .	Interest in controlled corporation	[REDACTED]	[REDACTED]
STA Pharmaceutical . . .	Beneficial interest	[REDACTED]	[REDACTED]

*Note:*

(1) As of the Latest Practicable Date, STA Pharmaceutical, a wholly-owned subsidiary of STA which is owned by WuXi AppTec (Shanghai) as to 98.56%, a wholly-owned subsidiary of WuXi AppTec, a company whose H shares are listed on the Stock Exchange (stock code: 2359) and A shares listed on the Shanghai Stock Exchange (stock code: 603259). As such, under the SFO, WuXi AppTec. (through its interest in a controlled corporation) is deemed to be interested in the [REDACTED] Shares held by STA Pharmaceutical.

Save as disclosed herein, our Directors are not aware of any other person who will, immediately following the completion of the [REDACTED] (assuming no changes to our issued and outstanding share capital between the Latest Practicable Date and the [REDACTED] and assuming the [REDACTED] is not exercised), have any interest and/or short positions in the Shares or underlying Shares which would fall to be disclosed to us pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, will be, directly or indirectly, interested in 5% or more of the issued voting shares of our Company or any other member of our Group. Our Directors are not aware of any arrangement which may at a subsequent date result in a change of control of our Company or any other member of our Group.